

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
28 April 2022 (28.04.2022)



(10) International Publication Number
WO 2022/087149 A3

(51) International Patent Classification:
C07K 14/55 (2006.01) C07K 19/00 (2006.01)

(21) International Application Number:
PCT/US2021/055877

(22) International Filing Date:
20 October 2021 (20.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/104,376 22 October 2020 (22.10.2020) US
63/181,075 28 April 2021 (28.04.2021) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: BACA, Manuel; 12 Coolidge Avenue, Lexington,
Massachusetts 02420 (US). GILMORE, Sarah A.; c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US). HUNG, Magdeleine S.; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US). JAVANBAKHT, Hassan; 340 Fremont
Street, Apt. 2910, San Francisco, California 94105 (US).
KANWAR, Manu; c/o Gilead Sciences, Inc., 333 Lake-
side Drive, Foster City, California 94404 (US). KHAN,
Shahzada; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, California 94404 (US). MUKHERJEE,
Prasenjit K.; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, California 94404 (US). NAGEL, Mark R.;
c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US). PAPALIA, Giuseppe; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US). TAM, Danny W.; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
THOMAS, Majlinda K.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: WAHLSTEN, Jennifer L. et al.; Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
02 June 2022 (02.06.2022)

(54) Title: INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE

(57) Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R α (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.

WO 2022/087149 A3